New combo tackles recurrent brain tumor: immunotherapy plus radiation before surgery

NCT ID NCT04977375

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining an immunotherapy drug (pembrolizumab) with targeted radiation before surgery is safe and feasible for people with recurrent glioblastoma, an aggressive brain cancer. Ten participants will receive the drug and radiation, then undergo standard surgery to remove the tumor. Researchers will monitor side effects and overall survival to see if this approach warrants further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab (an immunotherapy drug that helps the immune system fight cancer)
What this could lead to
If this approach is safe and shows promise, it could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is a very early, small trial (only 10 participants) focused on safety, not effectiveness. The combination may cause serious side effects or fail to improve survival. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cedars-Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.